Snobei over on Stockhouse posted a question to me:
"Re: FSHD.... After my father passed , my mother got diagnosed with Myesthenia Gravis. Bear, if u would be so kind as to explain if these are related and could RVX 208 bode well in this indication? As it is also an auto immune situation. Thx"
I messaged Snobei the following reply:
"I am no expert in autoimmune diseases, and I haven't studied much on the mechanism by which BET inhibitors benefit autoimmune diseases. However, it sure would be wonderful if a well tolerated drug like apabetalone extended benefits to autoimmune diseases including myasthenia gravis. Sorry I am not much more help."
I just wanted to additionally point out that apabetalone may only be the tip of the iceberg for the therapeutic potential of bromodomain inhibitors being developed by Resverlogix and Zenith. They each have thousands of compounds with varying pharmacokinetics and bromodomain binding properties. For example, I recall Resverlogix stating in the past year (last year's AGM I think) that they have follow-on compounds that can be: 1) selective for bromodomain-1 or bromodomain-2 of an individual BRD protein; and 2) compounds that are selective for individual BRD proteins (BRD4, BRD3, or BRD2). That offers a ton of untapped therapeutic potential.
Resverlogix previously “confirmed” a second clinical compound IND candidate and informed us that seven compounds have been chosen for follow-on testing (including RVX-206, RVX-641, RVX-2101, RVX-2113). What differentiates these seven additional compounds from apabetalone and what indications are these being developed for? What else is in the pipeline that we don't know about? If apabetalone is successful, the floodgates may open for the clinical development of these and other compounds.
One other compound we've heard about is RVX-297. It is also a BD2-selective compound but seems to have different binding properties than apabetalone (RVX-208). So it is possible that RVX-297 or similar follow on compunds may be superior to apabetalone for certain conditions, including inflammatory and autoimmune diseases.
https://www.ncbi.nlm.nih.gov/pubmed/27282480
https://www.ncbi.nlm.nih.gov/pubmed/28974538
https://www.ncbi.nlm.nih.gov/pubmed/28849824
BearDownAZ
